The Handbook of Biological Therapy
Drugs produced by molecular biological techniques, called the 'biologics', differ from the usual chemical medications. Their optimum use, and the detection and managemenet of adverse events, pose a significant challenge to the clinician. Licences for new biologics continue to be granted for the likes of rituximab, abatacept and certocizumals pegol. Intensive research is also defining new areas in which these drugs will be used in the future, increasing the number of practitioners using biologics. As the use of these drugs increases around the world, so the level of information needed by primary care practitioners and specialist prescribers needs to be expanded The Handbook of Biological Therapy provides the practising clinician with a practica guide to the use of Tumour Necrosis Factor Blocking Therapy (TNF-blockers), and important new class of biologic therapy for rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, and psoriatic arthritis. It is a comprehensive distillation of the authors' clinical experience with these drugs, combined with data from diverse databases offering practical advice on their uses, specific indications, supporting clinical trial data and safety issues, with the aim of making the use of these drugs easier for the busy clinician. All of the authors have been involved from the beginnings of the clinical trial programmes with these drugs and continue to use them in daily practice.
What people are saying - Write a review
We haven't found any reviews in the usual places.
7 other sections not shown
Other editions - View all
12 weeks 24 weeks abatacept ACR50 ACR adalimumab adalimumab 40 mg adverse events alefacept anakinra ankylosing spondylitis Ann Rheum anti-TNF anti-tumor necrosis factor Arthritis Rheum 2005 assessed BASDAI baseline biological therapies CDAI cells certolizumab pegol clinical response Clinical trial data compared concomitant controlled trial Crohn's disease disease duration DMARDs dose double-blind efalizumab efficacy etanercept fistulas Gastroenterology Heijde improvement increased induction inflammatory infliximab Infliximab 5 mg/kg infusion reactions lymphoma Mean age median methotrexate mg/week moderate to severe monoclonal antibody monotherapy months multicentre natalizumab NEngl open-label outcomes patients with active patients with moderate patients with RA patients with rheumatoid Pharmacokinetics Phase placebo placebo group placebo-controlled trial primary endpoint psoriasis psoriatic arthritis randomized received infliximab receiving placebo receptor remission reported Rheum Dis 2007 rheumatoid arthritis Rheumatol Rheumatology risk rituximab safety score subcutaneous sulfasalazine TNF inhibitors TNF-blocker therapy treated treatment tumor necrosis factor week 12 week 24